

# News Releases

Register for email alerts.

All Categories

Archive



Date	12/28/15
Title	Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absence
Download	<a href="#">PDF</a>
Date	12/16/15
Title	Valeant Provides Financial Guidance Update
Download	<a href="#">PDF</a>
Date	12/15/15
Title	Valeant Announces New U.S. Fulfillment Agreements With Walgreens; Plans To Further Extend Distribution To Independent Pharmacies
Download	<a href="#">PDF</a>
Date	11/20/15
Title	Valeant To Hold Investor Day On December 16 (Updated)
Download	<a href="#">PDF</a>
Date	11/12/15

**Title**

Valeant Pharmaceuticals To Present At Industry Conference

**Download**[PDF](#)**Date**

11/09/15

**Title**

Valeant To Hold Conference Call For Investors To Provide Business Update

**Download**[PDF](#)**Date**

11/06/15

**Title**

Valeant Issues Statement On Sales Of Company Stock

**Download**[PDF](#)**Date**

10/30/15

**Title**

Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committee

**Download**[PDF](#)**Date**

10/30/15

**Title**

Valeant To Terminate Relationship With Philidor

**Download**[PDF](#)**Date**

10/26/15

**Title**

Statements Of J. Michael Pearson, Chairman And CEO, And Robert Ingram, Lead Outside Director Of Valeant Pharmaceuticals

**Download**[PDF](#)**Date**

10/26/15

**Title**

Valeant Pharmaceuticals Confirms Appropriateness Of Accounting, Appoints Ad Hoc Board Committee To Review Philidor

**Download**

**PDF**

**Date**

10/26/15

**Title**

Valeant Pharmaceuticals Announces The Addition Of G. Mason Morfit To Its Board Of Directors

**Download**

**PDF**

**Date**

10/22/15

**Title**

Valeant Pharmaceuticals To Hold Investor Conference Call On October 26, 2015

**Download**

**PDF**

**Date**

10/21/15

**Title**

Valeant Pharmaceuticals Responds To Erroneous Report

**Download**

**PDF**

**Date**

10/19/15

**Title**

Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results

**Download**

**PDF**

**Date**

10/15/15

**Title**

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Synergetics USA, Inc.

**Download**

**PDF**

**Date**

10/15/15

**Title**

Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Synergetics USA, Inc.

**Download**

**PDF**

**Date**

10/14/15

**Title**

Valeant Provides Update Regarding Government Inquiries

**Download**[PDF](#)**Date**

10/13/15

**Title**

Valeant Pharmaceuticals Celebrates the Manufacturing of Four Billion Bottles of Eye Care Products at Bausch + Lomb's Greenville Solutions Plant

**Download**[PDF](#)**Date**

10/05/15

**Title**

Valeant Pharmaceuticals To Announce 2015 Third Quarter Results On October 19, 2015

**Download**[PDF](#)**Date**

10/05/15

**Title**

Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Synergetics USA, Inc.

**Download**[PDF](#)**Date**

09/22/15

**Title**

Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO™ (latanoprostene bunod)

**Download**[PDF](#)**Date**

09/08/15

**Title**

Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR®

**Download**[PDF](#)**Date**

09/02/15

**Title**

Valeant Pharmaceuticals To Acquire Synergetics USA

**Download**[PDF](#)**Date**

09/01/15

**Title**

Valeant And AstraZeneca To Partner On Brodalumab

**Download**[PDF](#)**Date**

08/25/15

**Title**

Valeant Pharmaceuticals Announces The Addition Of D. Robert Hale To Its Board Of Directors

**Download**[PDF](#)**Date**

08/20/15

**Title**

Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

**Download**[PDF](#)**Date**

07/23/15

**Title**

Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results

**Download**[PDF](#)**Date**

07/17/15

**Title**

Valeant Pharmaceuticals Agrees To Acquire Amoun Pharmaceutical

**Download**[PDF](#)**Date**

06/24/15

**Title**

Valeant Pharmaceuticals To Announce 2015 Second Quarter Results On July 23, 2015

**Download**

**PDF**

**Date**

06/23/15

**Title**

Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR®

**Download**

**PDF**

**Date**

06/11/15

**Title**

Valeant Pharmaceuticals To Appoint Robert L. Rosiello As Chief Financial Officer

**Download**

**PDF**

**Date**

05/27/15

**Title**

Salix Announces FDA Approval of Xifaxan® 550 mg for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea)

**Download**

**PDF**

**Date**

05/19/15

**Title**

Valeant Pharmaceuticals Announces 2015 Annual Meeting Results

**Download**

**PDF**

**Date**

05/12/15

**Title**

Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders

**Download**

**PDF**

**Date**

04/29/15

**Title**

Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results (PDF Version)

**Download**

**PDF**

**Date** 04/29/15

**Title**

Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results

**Download**

PDF

**Date** 04/29/15

**Title**

Valeant Announces CFO Succession Plan And Additional Executive Appointment

**Download**

PDF

**Date** 04/24/15

**Title**

RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

**Download**

PDF

**Date** 04/09/15

**Title**

Valeant Pharmaceuticals To Announce 2015 First Quarter Results On April 29, 2015

**Download**

PDF

**Date** 04/01/15

**Title**

Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015

**Download**

PDF

**Date** 04/01/15

**Title**

Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019

**Download**

PDF

**Date** 04/01/15

**Title**

Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021

**Download**[PDF](#)**Date**

04/01/15

**Title**

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals

**Download**[PDF](#)**Date**

04/01/15

**Title**

Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd.

**Download**[PDF](#)**Date**

03/27/15

**Title**

Valeant Pharmaceuticals Closes Offering Of \$1.45 Billion Of Common Shares

**Download**[PDF](#)**Date**

03/17/15

**Title**

Valeant Pharmaceuticals Prices Offering Of \$1.45 Billion Of Common Shares

**Download**[PDF](#)**Date**

03/16/15

**Title**

Valeant Pharmaceuticals Announces Offering Of \$1.45 Billion Of Common Shares

**Download**[PDF](#)**Date**

03/16/15

**Title**

Valeant And Salix Agree On Amended Terms To Merger Agreement



**Download**

**PDF**

**Date**

03/13/15

**Title**

Valeant Announces HSR Clearance For Salix Acquisition

**Download**

**PDF**

**Date**

03/13/15

**Title**

Valeant Announces Pricing Of Private Offering Of Senior Notes

**Download**

**PDF**

**Date**

03/11/15

**Title**

Valeant Comments On Endo Offer To Acquire Salix

**Download**

**PDF**

**Date**

03/09/15

**Title**

Valeant Announces Launch Of Private Offering Of Senior Notes

**Download**

**PDF**

**Date**

02/25/15

**Title**

PROVENGE® (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer

**Download**

**PDF**

**Date**

02/22/15

**Title**

Valeant To Acquire Salix Pharmaceuticals For \$158.00 Per Share In Cash

**Download**

**PDF**

**Date** 02/22/15

**Title**

Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results

**Download**

[PDF](#)

**Date** 02/10/15

**Title**

Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon

**Download**

[PDF](#)

**Date** 02/05/15

**Title**

Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)

**Download**

[PDF](#)

**Date** 02/05/15

**Title**

Valeant Pharmaceuticals To Announce 2014 Fourth Quarter And Full Year Results On February 24, 2015

**Download**

[PDF](#)

**Date** 01/29/15

**Title**

Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)

**Download**

[PDF](#)

**Date** 01/20/15

**Title**

Bausch + Lomb Introduces New Software and Advanced OCT Imaging System for VICTUS® Femtosecond Laser Platform

**Download**

[PDF](#)

**Date** 01/15/15

**Title**  
Valeant Announces Redemption of All of the Approximately \$500 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018

**Download** [PDF](#)

**Date** 01/15/15

**Title**  
Valeant Announces Pricing Of Private Offering Of Senior Notes

**Download** [PDF](#)

**Date** 01/15/15

**Title**  
Valeant Announces Launch of Private Offering of Senior Notes

**Download** [PDF](#)

**Date** 01/06/15

**Title**  
Valeant Pharmaceuticals To Present At The J.P. Morgan 2015 Healthcare Conference

**Download** [PDF](#)



#### Investor Inquiries

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)

877-281-6642

514-856-3855 (Canada)

#### Media inquiries

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)

908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.  
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION**

